NASDAQ:ETNB 89bio Inc Target PTs 29 --> 20 --> 43 and higher 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment...
Price recently filled the gap at $5 and has since closed higher for 3 consecutive days creating a "3 white soldier" pattern. In addition the ADX displays a strong trend with a value of 39 with the D+ indicator rising. Targets: $6.46, $7.81
Just another chart with numbers looking good. My first TP as marked.
No financial advice, just an idea May be first target go to 28.
ETNB long, longer-term play 89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA. Pre-revenue, early stage company.
Both its technical analysis and fundamental reports look great. This is a perfect time to buy this stock. TP 22.76
Both its technical analysis and fundamental reports look great. This is a perfect time to buy this stock.
This is a technical analysis . this stock is headed towards the $35 mark. watch it. This is not a signal. please trade are your own risk.
info from secform4.com july8th 275,000 shares bought at $27.5 $7,562,500 dollars worth 10% owner september 21rst 1,300,000 shares bought at $28 $36,400,000 dollars worth director 10% owner a few days after had bank of america upgrade from 37 to 43 dollars target posted on finviz.com in a long position up to around 43 dollars per share